Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 1.75
- Piotroski Score 2.00
- Grade Outperform
- Symbol (MIRM)
- Company Mirum Pharmaceuticals, Inc.
- Price $40.67
- Changes Percentage (0.54%)
- Change $0.22
- Day Low $38.16
- Day High $41.00
- Year High $45.23
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease. It also develops Volixibat drug for treatment of intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Mirum Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Foster City, California.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/12/2024
- Fiscal Year End N/A
- Average Stock Price Target $52.50
- High Stock Price Target $75.00
- Low Stock Price Target $39.00
- Potential Upside/Downside N/A
- Consensus Rating Strong Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$3.74
- Trailing P/E Ratio -6.7
- Forward P/E Ratio -6.7
- P/E Growth -6.7
- Net Income $-163,415,000
Income Statement
Quarterly
Annual
Latest News of MIRM
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Mirum Pharmaceuticals, Inc. (MIRM) Stock Price, News, Quote & History - Yahoo Finance
Mirum Pharmaceuticals is a biopharmaceutical company specializing in novel therapies for rare diseases. Their lead product is LIVMARLI for cholestatic pruritus in Alagille syndrome....
By Yahoo! Finance | 2 months ago -
Mirum Pharmaceuticals (NASDAQ:MIRM) delivers shareholders solid 23% CAGR over 5 years, surging 11% in the last week alone
Investing in shares carries risks, but can also lead to substantial gains. Mirum Pharmaceuticals saw its share price increase by 185% in the last five years. Although the company didn't profit recentl...
By Yahoo! Finance | 3 months ago
